The Global Immune-Nutrition Inflammation Index for Predicting Coronary Slow Flow Phenomenon in Patients with Angina and No Obstructive Coronary Arteries

全球免疫营养炎症指数预测无阻塞性冠状动脉心绞痛患者的冠状动脉慢血流现象

阅读:2

Abstract

BACKGROUND: Chronic inflammatory responses are involved in the initiation and development of the coronary slow flow phenomenon (CSFP). However, as a newly developed immuno-nutritional inflammation indicator, the global immune-nutrition inflammation index (GINI) has not been well elaborated for predicting CSFP in patients with angina and no obstructive coronary arteries (ANOCA). METHODS: A total of 1422 individuals with ANOCA were consecutively included in this study, of whom 93 developed CSFP (CSFP group). We selected 186 (1:2 matched) age- and sex-matched patients with ANOCA and angiographically proven normal coronary blood flow as the controls (the control group). Multivariate logistic regression analysis was used to investigate predictors of CSFP in patients with ANOCA. The optimal cutoff values for GINI were calculated. RESULTS: In total, 93 patients developed CSFP, including 29% (27) in one vessel, 28% (26) in two vessels, and 43% (40) in three vessels. Patients with CSFP had an elevated CRP level, white blood cell (WBC) count, neutrophil count, GINI, fasting blood glucose (FBG) level, and a lower lymphocyte count (P<0.05). Multivariate logistic analysis showed that the GINI and FBG levels were independent predictors of CSFP in patients with ANOCA. Moreover, we found that the more vessels affected by CSFP, the higher the GINI level. The receiver operating characteristic (ROC) showed that GINI had a better predictive value than indicators alone. When the GINI AISI was >84.1, the sensitivity and specificity were 88.2% and 58.7%, respectively [The Area Under the ROC curve (AUC): 0.774; 95% CI: 0.721-0.827; P < 0.001]. CONCLUSION: Elevated GINI is a reliable predictor of CSFP in patients with ANOCA. Moreover, GINI had a superior predictive value compared to the indicators alone. As a newly developed inflammatory indicator, GINI can be used for further risk stratification of patients with ANOCA.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。